The Director General of the Agence nationale de sécurité du médicament et des produits de santé may suspend or remove the registration of a medicinal product from the list provided for in article R. 5121-202 if the conditions laid down in this article are no longer met or for any public health reason, in particular when the benefit/risk balance of the medicinal product as defined in the first paragraph of article L. 5121-9 is being reassessed.
The decision of the Director General provided for in the previous paragraph must state the reasons on which it is based and may only be taken, except in cases of urgency, after the applicant has been given the opportunity to submit written observations and, where appropriate, at his request, oral observations.